Obstructive sleep apnoea and the progression of thoracic aortic aneurysm: a prospective cohort study.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
30
08
2020
accepted:
26
10
2020
pubmed:
21
11
2020
medline:
6
7
2021
entrez:
20
11
2020
Statut:
epublish
Résumé
Obstructive sleep apnoea (OSA) is associated with an increased prevalence of aortic aneurysms and it has also been suggested that severe OSA furthers aneurysm expansion in the abdomen. We evaluated whether OSA is a risk factor for the progression of ascending thoracic aortic aneurysm (TAA). Patients with TAA underwent yearly standardised echocardiographic measurements of the ascending aorta over 3 years and two level III sleep studies. The primary outcome was the expansion rate of TAA in relation to the apnoea-hypopnoea index (AHI). Secondary outcomes included surveillance for aortic events (composite end-points of rupture/dissection, elective surgery or death). Between July 2014 and March 2020, 230 patients (median age 70 years, 83.5% male) participated in the cohort. At baseline, 34.8% of patients had AHI ≥15 events·h OSA may be a modest but independent risk factor for faster TAA expansion and thus potentially contributes to life-threatening complications in aortic disease.
Sections du résumé
BACKGROUND
Obstructive sleep apnoea (OSA) is associated with an increased prevalence of aortic aneurysms and it has also been suggested that severe OSA furthers aneurysm expansion in the abdomen. We evaluated whether OSA is a risk factor for the progression of ascending thoracic aortic aneurysm (TAA).
METHODS
Patients with TAA underwent yearly standardised echocardiographic measurements of the ascending aorta over 3 years and two level III sleep studies. The primary outcome was the expansion rate of TAA in relation to the apnoea-hypopnoea index (AHI). Secondary outcomes included surveillance for aortic events (composite end-points of rupture/dissection, elective surgery or death).
RESULTS
Between July 2014 and March 2020, 230 patients (median age 70 years, 83.5% male) participated in the cohort. At baseline, 34.8% of patients had AHI ≥15 events·h
CONCLUSION
OSA may be a modest but independent risk factor for faster TAA expansion and thus potentially contributes to life-threatening complications in aortic disease.
Identifiants
pubmed: 33214207
pii: 13993003.03322-2020
doi: 10.1183/13993003.03322-2020
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02204774']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©ERS 2021.
Déclaration de conflit d'intérêts
Conflict of interest: T. Gaisl reports personal fees from Bayer AG (consulting), outside the submitted work. Conflict of interest: P. Rejmer has nothing to disclose. Conflict of interest: M. Roeder has nothing to disclose. Conflict of interest: P. Baumgartner has nothing to disclose. Conflict of interest: N.A. Sievi has nothing to disclose. Conflict of interest: S. Siegfried has nothing to disclose. Conflict of interest: S.F. Stämpfli reports personal fees for consultancy from Amgen, AstraZeneca, Bayer, Novartis and Pfizer, outside the submitted work. Conflict of interest: R. Thurnheer has nothing to disclose. Conflict of interest: J.R. Stradling reports personal fees for consultancy from Bayer AG and ResMed, outside the submitted work. Conflict of interest: F.C. Tanner has nothing to disclose. Conflict of interest: M. Kohler reports personal fees for consultancy from Bayer AG, AstraZeneca, Novartis, GSK, Boehringer Ingelheim and Mundipharma, outside the submitted work, and is founder and owner of the “Deep Breath Initiative” a company that provides services in the field of exhaled breath analysis.